Facet Joint and Medial Branch Block Injections for Spinal Pain (for Louisiana Only)
Medical policy governing the use, indications, and coding of facet joint injections and medial branch (medial nerve) blocks for diagnosis and treatment of spinal pain for Louisiana Medicaid members and providers.
Added language clarifying that the listed circumstances are unproven and not medically necessary for Facet Joint Injections/Medial Branch Blocks due to insufficient evidence of efficacy.
Updated Clinical Evidence and References sections to reflect the most current information.
Retired policy for Louisiana plan membership on Apr. 1, 2026.
Coverage Criteria
inv-01: Initial diagnostic injection
Covered when ALL of the following are met
From policy indications
inv-02: Confirmatory diagnostic injection
Covered when ALL of the following are met
Second block used to confirm validity before RFA
inv-03: Therapeutic injections (when RFA not considered)
Covered when ALL of the following are met
Policy states therapeutic injections are proven/medically necessary when RFA is not considered
inv-04: Therapeutic injections - Not medically necessary
Not medically necessary when ANY of the following apply
Policy explicitly states therapeutic injections at these levels are unproven/not medically necessary in parts of the document
inv-05: Diagnostic medial branch blocks — criteria for acceptable diagnostic confirmation
Covered when diagnostic criteria are met per guideline recommendations
Some societies accept ≥50% as positive prognostic block; document criterion applied
inv-06: Therapeutic medial branch or intra-articular facet injections — coverage stance
Therapeutic injections are generally not supported as routine long-term therapy based on current evidence
ASIPP and other societies provide conditional recommendations for select uses; NASS and others report insufficient evidence
inv-07: Evidence limitations and interpretation
Evidence summary and limitations informing coverage
Guideline panels recommend further high-quality randomized trials
inv-08: Therapeutic Facet Joint Injections / Medial Branch Blocks — Insufficient Evidence / Not Medically Necessary
Not recommended/insufficient evidence for therapeutic use when ANY of the following apply
Based on NASS statements that evidence is insufficient (Grade I) and retrospective/case-series limitations.
NASS: single diagnostic block with 50% relief not supported for predicting durable benefit.
Therapeutic facet joint and medial branch block injections at the cervical, thoracic, and lumbar levels are identified in this policy as unproven and not medically necessary when proposed for routine therapeutic use because the available evidence is insufficient to demonstrate consistent efficacy or safety. The policy distinguishes diagnostic injections (which may be covered when criteria are met) from therapeutic injections and specifies that therapeutic procedures intended for long‑term pain management lack supportive high‑quality evidence and therefore may be excluded from coverage in many circumstances.
Specific exclusions in the policy call out therapeutic facet/medial branch injections as not medically necessary across spine regions; providers should document that diagnostic criteria and conservative treatment requirements were met if claiming therapeutic intent, and recognize that therapeutic use without those conditions may be denied.
Ultrasound guidance for facet joint and medial branch injections is addressed separately from fluoroscopy/CT guidance. The policy notes that there is no peer‑reviewed evidence demonstrating overall health benefit of ultrasound guidance compared with fluoroscopy or CT, and clinical guidelines do not currently recommend ultrasound as superior for spinal facet procedures.
Meta‑analytic data cited in the policy also report a measurable risk of incorrect needle placement with ultrasound guidance when confirmed by fluoroscopy or CT (pooled analyses showing an ~11–13% risk difference of incorrect placement), and authors emphasize operator‑dependence and heterogeneity in training and technique as limitations to generalizing ultrasound guidance as equivalent or superior to image‑guided (fluoroscopy/CT) approaches.
The policy explicitly states that no published literature addresses intra‑articular facet joint injections for thoracic spine pain. Given this absence of evidence, clinicians are advised to carefully weigh risks and benefits and consider alternative conservative or palliative options when treating thoracic facetogenic pain.
Because available studies and guideline statements focus primarily on cervical and lumbar regions, the lack of thoracic data contributes to the policy’s stance that therapeutic intra‑articular injections in the thoracic spine remain unsupported by evidence.
Multiple systematic reviews, guideline statements, and the policy narrative describe the evidence for therapeutic facet joint and medial branch injections as limited by low quality, small trials, heterogeneous methods, and inconsistent outcomes. Overall, there is insufficient high‑quality evidence to conclude that therapeutic injections reliably provide long‑term pain relief or functional benefit.
For example, a recent systematic review/meta‑analysis summarized mixed findings and exploratory results; while some single‑arm analyses report short‑term improvements, randomized comparisons (local anesthetic versus anesthetic plus steroid) did not show consistent statistical benefit for therapeutic steroid use, supporting the policy’s cautious stance against routine therapeutic application.
The policy aligns with guideline panels that do not recommend routine therapeutic facet injections for acute or subacute low back pain and that advise against repeat intra‑articular injections when prior injections have failed to provide lasting functional improvement. Specifically, ACOEM guidance labels therapeutic intra‑articular injections as not recommended for acute/subacute LBP and advises that repeat injections are moderately not recommended when durable benefit is absent.
Consequently, routine repeat therapeutic injections or use for acute/subacute presentations are discouraged and may be considered not medically necessary when they do not meet guideline‑based indications or fail to produce sustained functional improvement.
Based on the totality of evidence and updated policy language, the document identifies therapeutic facet joint injections and therapeutic medial branch blocks intended for long‑term pain management as unproven and not medically necessary in the listed circumstances. This determination reflects guideline conclusions and systematic review findings that evidence quality is low or inconsistent for therapeutic benefit.
The policy clarifies that diagnostic injections performed according to coverage criteria (including conservative therapy prerequisites and confirmatory blocks when indicated) remain distinct from therapeutic interventions, and that the recent coverage revision explicitly marked the therapeutic uses described above as unproven/not medically necessary.
Coding
| 0213T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level. |
| 0214T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure). |
| 0215T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure). |
| 0216T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level. |
| 0217T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure). |
| 0218T | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure). |
| 64490 | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level. |
| 64491 | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure). |
| 64492 | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure). |
| 64493 | Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level. |
| M47.812 | Spondylosis without myelopathy or radiculopathy, cervical region. |
| M47.813 | Spondylosis without myelopathy or radiculopathy, cervicothoracic region. |
| M47.814 | Spondylosis without myelopathy or radiculopathy, thoracic region. |
| M47.815 | Spondylosis without myelopathy or radiculopathy, thoracolumbar region. |
| M47.816 | Spondylosis without myelopathy or radiculopathy, lumbar region. |
| M47.817 | Spondylosis without myelopathy or radiculopathy, lumbosacral region. |
| M47.819 | Spondylosis without myelopathy or radiculopathy, site unspecified. |
| M47.892 | Other spondylosis, cervical region. |
| M47.893 | Other spondylosis, cervicothoracic region. |
| M47.894 | Other spondylosis, thoracic region. |
Provider Actions & Requirements
Prior Authorization Note
Prior authorization may be required for the listed facet joint and medial branch injection procedure codes. Verify plan-specific prior authorization requirements before scheduling.
- Confirm prior authorization requirements for all applicable CPT/HCPCS codes prior to performing injections
Conservative Therapy & Diagnostic Block Response
Conservative therapy is recommended before prognostic/diagnostic facet interventions. Document a trial of conservative care and the patient's response to diagnostic blocks; failure to do so may result in denial.
- Document at least 4 weeks (often 6 weeks or more per specialty guidance) of conservative therapy including types of treatment (e.g., NSAIDs, physical therapy, exercise, CBT, spinal manipulation) and duration
- Concomitant conservative measures should be continued when performing prognostic blocks
Prior Authorization Guidance for Therapeutic Facet/Medial Branch Interventions
Therapeutic medial branch/facet injections (intended for long‑term management) are generally considered unproven due to insufficient evidence. Prior authorization requests for therapeutic blocks should clearly justify why other established options (including radiofrequency ablation where appropriate) are not being used.
- Therapeutic MBBs/IA facet injections for chronic spinal pain are considered unproven/not medically necessary in many cases; expect higher denial risk without strong justification
- If a therapeutic block is requested, provide rationale why RFA or other recommended treatments are not appropriate
Conservative Care Prerequisite
Requests may be denied if the patient has not completed an adequate trial of conservative care or if documentation does not support consideration of radiofrequency ablation when appropriate.
- Denial risk if < 4 weeks of conservative therapy are documented (specialty guidance may recommend ≥6 weeks or 3 months for certain presentations)
- Denial risk if RFA is clinically appropriate but not considered or documented in the treatment plan
RF Ablation Consideration
When RF ablation is an appropriate therapeutic option at the requested level(s), documentation should show that RFA was considered. Failure to consider RFA when indicated may adversely affect coverage decisions.
- State whether radiofrequency denervation/ablation is being considered and rationale if it is not being pursued
Required Clinical Documentation
Provide complete clinical documentation with every request. Incomplete records demonstrating lack of conservative therapy, inadequate diagnostic response, or missing procedural details may result in denial or delay.
- Clinical history including pain location, intensity (1–10 scale), exacerbating/relieving factors, and physical exam findings (e.g., pain with facet loading maneuvers)
- Documentation of prior conservative treatments, modalities used, durations, and objective response
- Imaging findings that exclude other pain sources (e.g., radiculopathy, fracture, infection, tumor)
- If diagnostic blocks performed, document agent, concentration, injected volume, onset and duration of pain relief, and percentage pain reduction
Procedure & Device Documentation
Record procedural and device details for all facet/medial branch injections. Include targeted joints/medial branches, laterality and spinal levels, imaging/guidance modality, injectate(s) and volumes, and any devices used.
- Targeted joint(s) or medial branch(es) and spinal level(s) and side
- Imaging/guidance method (fluoroscopy, CT, or ultrasound) and use of contrast if applicable
- Medications and doses (local anesthetic type and concentration, steroid type if used) and total injectate volume
- Devices or implants present and any device-related considerations
Confirmatory Diagnostic Block Requirement
Confirmatory diagnostic blocks: a second diagnostic injection is required to validate a positive response before proceeding to neurotomy/RFA except in select circumstances noted by specialty guidance. The second injection should reproduce the effect at the same level and side and meet the policy's pain‑relief thresholds.
- Second block should be at the same level and side as the initial diagnostic block when confirming the same joint
- Document that the initial block produced the expected minimum duration of relief and functional improvement
- Policy/ASRA thresholds: consider ≥50% relief as positive for many diagnostic purposes; some specialty guidance recommends ≥80% relief for confirmatory dual‑block paradigms prior to RFA
Conservative‑First Approach & Considerations
Adopt a conservative-first approach: use noninvasive and conservative treatments prior to facet interventions and weigh risks/benefits. Consider patient‑specific factors (age, comorbidities, anticoagulation, prior response to injections) when selecting intervention strategy, and consider conservative or palliative care options when appropriate.
- Document the conservative therapies attempted and the clinical rationale for proceeding to diagnostic injections
- In patients at higher risk from RFA or with strong prior benefit from corticosteroid-containing blocks, the addition of steroid may be reasonable for intermediate-term relief per specialty guidance
- Ensure target volumes for medial branch and intra-articular injections follow specialty recommendations to minimize spread (e.g., cervical MBB ≤0.3 mL; lumbar MBB total volume <0.5 mL; IA lumbar <1.5 mL)
Conservative Treatment Requirements
inv-41: Documented trial of conservative therapy prior to diagnostic injection — minimum 4 weeks
Covered when ALL of the following are met
Conservative therapies include medications (e.g., NSAIDs), physical therapy, spinal manipulation, CBT, or other individualized interventions
inv-42: Document prior conservative therapy and duration — Lumbar ~3 months; Cervical at least 6 weeks (guideline ranges vary)
Covered when ALL of the following are met
Guideline-recommended durations vary by society; document specifics in chart
Frequency & Procedural Limits
Imaging Requirements
Use and document appropriate image guidance (fluoroscopy/CT or ultrasound) per code
Use image guidance per the coded procedure: codes specify either ultrasound guidance or image guidance (fluoroscopy/CT); document the imaging modality used in the procedure note.
- Some CPT codes (0213T–0218T) indicate ultrasound guidance; others (64490–64495) indicate fluoroscopy or CT guidance.
- Document which modality (fluoroscopy, CT, or ultrasound) was used for the injection.
CT or MRI recommended prior to AO/AA cervical joint injections
Obtain pre‑procedural advanced cervical imaging (CT or MRI) before AO/AA (C0–C1, C1–C2) joint injections to ascertain pathology and guide needle trajectory; document the imaging in the record.
- ASRA recommends CT or MRI prior to AO/AA cervical injections to help guide needle trajectory and determine pathology.
- Include imaging reports in the pre‑procedure documentation.
Document devices/drugs used and reference imaging/device guidance in literature
Document any devices or drugs used and note that devices/drugs used in these procedures may be subject to FDA regulation; reference literature guidance for imaging modality selection when applicable.
- Procedural devices/drugs may be regulated by the FDA even though the procedures themselves are not.
- Imaging modality guidance and device/drug considerations are referenced in the literature and should be documented.
Background
Facet joint injections and medial branch (medial nerve) blocks are interventional procedures used primarily to diagnose facet‑mediated spinal pain and, in some clinical contexts, to provide temporary symptomatic relief. Diagnostic blocks aim to reproduce the patient’s usual pain with an anesthetic and demonstrate meaningful pain reduction relative to the expected duration of the anesthetic; the policy uses a ≥50% pain relief threshold for a positive diagnostic response when documented for at least the expected anesthetic duration.
Diagnostic medial branch blocks are often performed as a series (dual blocks) to reduce false positives, and coverage for diagnostic injections requires documentation of conservative care (minimum 4 weeks), relevant physical exam findings (e.g., facet loading maneuvers), imaging excluding alternative causes, and that radiofrequency denervation is being considered when applicable.
Definitions
Not Covered / Exclusions
NOT COVERED: Therapeutic facet joint injections and therapeutic medial branch block injections intended for long‑term management of spinal pain at the cervical, thoracic, or lumbar levels are declared unproven and not medically necessary in the circumstances listed by this policy due to insufficient evidence of efficacy and safety.
This not‑covered stance follows the policy revisions effective 07/01/2025 and is supported by guideline conclusions and systematic reviews that found limited, low‑quality, or inconsistent evidence for therapeutic benefit; providers seeking coverage for therapeutic use should ensure diagnostic criteria, conservative therapy trials, and documentation requirements are satisfied and consider radiofrequency denervation where appropriate.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.